Every 10-Q that Acme United Corporation (ACU) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ACU and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ACU filings page.
Acme United Corporation reported strong top-line growth for the quarter ended June 30, 2026, led by first aid/medical products and the newly acquired My Medic direct-to-consumer business. Consolidated net sales were $62,716,000 versus $53,996,000 a year earlier, and six‑month sales were $115,017,000 versus $99,954,000.
Gross profit improved to $26,688,000 or 42.6% of sales for the quarter, helped by the higher-margin My Medic line. However, SG&A rose to $19,858,000 (31.7% of sales) due to My Medic advertising and higher personnel costs, and tariff-affected inventory pressured results. Operating income was $6,830,000 for the quarter and $8,574,000 year-to-date, close to prior-year levels. Net income was $5,051,000 for the quarter and $6,034,000 for six months, with diluted EPS of $1.22 and $1.46, respectively.
Operating cash flow strengthened to $10,887,000 for the first half, supporting the $18,500,000 My Medic asset acquisition and lifting total assets to $200,645,000 and equity to $121,302,000. Revolving credit borrowings increased to $22,637,000, and the company subsequently replaced its facility with a new $65,000,000 syndicated credit line maturing in 2029, maintaining ample liquidity while managing higher tariffs and geopolitical supply-chain risks.
Acme United’s first quarter 2026 showed higher sales but lower profit. Net sales rose to $52.3 million, up 14% from a year earlier, helped by stronger first aid and medical demand and the January acquisition of My Medic. Excluding My Medic, comparable sales grew 6%.
Net income fell to $1.0 million from $1.7 million as higher tariffs, quality investments and personnel costs pushed selling and administrative expenses up to $19.0 million. Diluted EPS declined to $0.24 from $0.41. Operating cash flow was a use of $2.2 million, mainly from higher receivables and inventory.
The company bought My Medic for $18.6 million (including contingent and holdback amounts); the business added $3.4 million in revenue. To fund the deal and working capital, borrowings under the revolving credit facility increased to $33.0 million, raising the long‑term debt to equity ratio to 36.3%. Management says it remains in covenant compliance and views existing cash and credit capacity as sufficient for the next twelve months.
Acme United (ACU) reported steady Q3 2025 results. Net sales were $49,063,000, up 2% year over year, with diluted EPS of $0.46 (basic $0.50). Gross margin improved to 39.1% from 38.5%, while SG&A rose to 33.0% of sales. Operating income was $3,007,000, slightly above last year. Net income was $1,903,000 versus $2,226,000 a year ago.
The U.S. segment grew modestly on first aid and medical products, Canada increased 5% (strength in first aid), and Europe rose 13% on e‑commerce school and office products. For the nine months, sales were $149,018,000 and diluted EPS held at $2.03.
Liquidity remained solid: operating cash flow reached $10,079,000 year to date, working capital increased to $76,619,000, and the current ratio improved to 4.47. The company extended its $65 million SOFR+1.75% revolving credit facility to May 31, 2027 and purchased a Mt. Pleasant, TN manufacturing and distribution center for approximately $6.0 million. Management disclosed a previously identified material weakness in IT general controls remains, with remediation expected by December 31, 2025.
ACU Q2-25 10-Q highlights:
- Revenue: Q2 net sales $54.0 M, -3% YoY; 6-mo $100.0 M, flat YoY.
- Profitability: Q2 gross margin 41.0% (40.8% LY); operating income $6.4 M (flat); net income $4.8 M, +7% YoY; diluted EPS $1.16 vs $1.09. 6-mo net income $6.4 M, +5%; diluted EPS $1.57 vs $1.47.
- Segment trends: U.S. sales -5% on tariff-driven back-to-school order cancellations; Canada +28% on first-aid demand; Europe -3% (shipment delays).
- Cash & liquidity: Operating cash inflow $3.0 M vs $-3.3 M LY; capex $3.0 M. Cash $3.6 M; revolver borrowings $16.4 M (-$1.3 M YTD); mortgage $10.2 M; long-term-debt-to-equity 22.9%.
- Balance sheet: Working capital $77.9 M; current ratio 4.3x. Inventory $57.3 M, turnover unchanged at 2.1x.
- Credit facility: $65 M HSBC revolver maturity extended to 5/31/27 at SOFR +1.75%.
- Controls: Material weakness in IT general controls persists; remediation expected by YE-25.
- Outlook drivers: tariff volatility, supply-chain diversification, demand seasonality (back-to-school), ongoing integration of Elite First Aid (no new financial impact disclosed).